 Shares of Insmed NASDAQ:INSM were unchanged at 21.05 after the company reported Q1 results.Quarterly Results Earnings per share increased 22.92 year over year to 0.74, which missed the estimate of 0.71.Revenue of 36,860,000 higher by 68.30 from the same period last year, which beat the estimate of 34,800,000.Looking Ahead Earnings guidance hasnt been issued by the company for now.Revenue guidance hasnt been issued by the company for now.Conference Call Details Date: Apr 30, 2020View more earnings on INSMTime: 11:01 AM ETWebcast URL: Stock Performance 52-week high: 34.94Companys 52-week low was at 12.09Price action over last quarter: down 20.02Company Description Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The companys first commercial product is ARIKAYCE amikacin liposome inhalation suspension, approved in the US for the treatment of Mycobacterium avium complex MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The companys earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.See more from Benzinga Recap: Patrick Industries Q1 Earnings Superior Group: Q1 Earnings Insights Recap: Independent Bank Q1 EarningsC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 